Youcare Pharmaceutical (SH:688658) Xin Lang Cai Jing·2025-10-31 03:58Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a 5% increase in stock price, reaching 21.62 CNY per share, with a total market capitalization of 9.729 billion CNY [1] - Yuyuan Pharmaceutical focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] Group 2 - Huashan Fund has a significant holding in Yuyuan Pharmaceutical, with the Huashan CSI 1000 Index Enhanced A fund holding 10,500 shares, representing 0.4% of the fund's net value [2] - The Huashan CSI 1000 Index Enhanced A fund has achieved a year-to-date return of 25.63% and a one-year return of 28.95% [2] - The fund manager, Zhang Xu, has a tenure of 5 years and 168 days, with the best fund return during this period being 144.8% [3]